CY1125167T1 - Διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια σκληρυνσης κατα πλακας - Google Patents
Διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια σκληρυνσης κατα πλακαςInfo
- Publication number
- CY1125167T1 CY1125167T1 CY20221100292T CY221100292T CY1125167T1 CY 1125167 T1 CY1125167 T1 CY 1125167T1 CY 20221100292 T CY20221100292 T CY 20221100292T CY 221100292 T CY221100292 T CY 221100292T CY 1125167 T1 CY1125167 T1 CY 1125167T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diseases
- pharmaceutical compositions
- formula
- methods
- sheldering
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 abstract 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 abstract 1
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 abstract 1
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 abstract 1
- 208000029523 Interstitial Lung disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002314 neuroinflammatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Μία ένωση σύμφωνα προς τον Τύπο (la): όπου L1, G και R1 είναι όπως περιγράφεται στο παρόν.Η παρούσα εφεύρεση αφορά σε νέες ενώσεις σύμφωνα προς τον Τύπο (Ι) που ανταγωνίζονται GPR84, ένα συνδεδεμένο με G-πρωτεΐνη υποδοχέα ο οποίος ενέχεται σε φλεγμονώδεις καταστάσεις και μεθόδους για την παραγωγή αυτών των νέων ενώσεων, φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις και μεθόδους για την αποτροπή ή/και θεραπεία φλεγμονωδών καταστάσεων (για παράδειγμα, ασθενειών φλεγμονώδους εντέρου (IBD), ρευματοειδούς αρθρίτιδας, αγγειίτιδας, ασθενειών του πνεύμονα (π.χ. χρόνιας αποφρακτικής πνευμονοπάθειας (COPD) και διάμεσων ασθενειών του πνεύμονα, (π.χ., ιδιοπαθή πνευμονική ίνωση (IPF))), νευροφλεγμονωδών καταστάσεων, μολυσματωδών ασθενειών, αυτοάνοσων ασθενειών, ενδοκρινών ή/και μεταβολικών ασθενειών ή/και ασθενειών που περιλαμβάνουν εξασθένηση των λειτουργιών ανοσοκυττάρου με χορήγηση μιας ένωσης της εφεύρεσης.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578979P | 2011-12-22 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125167T1 true CY1125167T1 (el) | 2024-09-20 |
Family
ID=47520068
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101053T CY1119434T1 (el) | 2011-12-22 | 2017-10-11 | Νεες διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια φλεγμονωδων διαταραχων |
| CY20221100292T CY1125167T1 (el) | 2011-12-22 | 2022-04-18 | Διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια σκληρυνσης κατα πλακας |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101053T CY1119434T1 (el) | 2011-12-22 | 2017-10-11 | Νεες διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια φλεγμονωδων διαταραχων |
Country Status (35)
| Country | Link |
|---|---|
| US (5) | US8927543B2 (el) |
| EP (3) | EP3378862B1 (el) |
| JP (1) | JP6062453B2 (el) |
| KR (1) | KR102012268B1 (el) |
| CN (1) | CN103998448B (el) |
| AR (1) | AR089284A1 (el) |
| AU (1) | AU2012357067B2 (el) |
| BR (1) | BR112014015142B1 (el) |
| CA (1) | CA2859578C (el) |
| CL (1) | CL2014001664A1 (el) |
| CO (1) | CO7010835A2 (el) |
| CR (1) | CR20140305A (el) |
| CY (2) | CY1119434T1 (el) |
| DK (2) | DK2794604T3 (el) |
| EA (1) | EA023826B1 (el) |
| ES (2) | ES2911449T3 (el) |
| HK (1) | HK1201528A1 (el) |
| HR (2) | HRP20220456T1 (el) |
| HU (1) | HUE12812237T4 (el) |
| IL (2) | IL233212B (el) |
| IN (1) | IN2014MN01033A (el) |
| LT (2) | LT3378862T (el) |
| MX (1) | MX351681B (el) |
| NI (1) | NI201400060A (el) |
| PE (1) | PE20141685A1 (el) |
| PH (1) | PH12014501178A1 (el) |
| PL (2) | PL2794604T3 (el) |
| PT (2) | PT3378862T (el) |
| SG (1) | SG11201403169PA (el) |
| SI (2) | SI3378862T1 (el) |
| TW (1) | TWI567073B (el) |
| UA (1) | UA111767C2 (el) |
| UY (1) | UY34545A (el) |
| WO (1) | WO2013092791A1 (el) |
| ZA (1) | ZA201404607B (el) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2794627T (lt) | 2011-12-22 | 2019-01-10 | Alios Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| CN104870445B (zh) * | 2012-12-20 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂) |
| GB201319677D0 (en) * | 2013-11-07 | 2013-12-25 | Eth Z Rich | Cyclopropanation |
| GB201411241D0 (en) * | 2014-06-25 | 2014-08-06 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| EP3594221B1 (en) | 2017-03-06 | 2021-06-30 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Gpr84 receptor antagonist and use thereof |
| EP3403649A1 (en) * | 2017-05-16 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Inhibitors and antagonists of gpr84 for the treatment of endometriosis |
| BR112020008425A2 (pt) * | 2017-11-15 | 2020-11-17 | Galapagos N.V. | compostos e composições farmacêuticas dos mesmos para uso no tratamento de doenças fibróticas |
| GEP20247585B (en) | 2019-12-19 | 2024-01-25 | Bayer Ag | Furoindazole derivatives |
| WO2021123394A1 (en) | 2019-12-20 | 2021-06-24 | University Of Copenhagen | G protein-coupled receptor modulators and a pharmaceutical composition |
| WO2022112186A1 (en) | 2020-11-24 | 2022-06-02 | Galapagos Nv | Compound for use in and methods of treatment of fibrotic diseases |
| EP4298102A1 (en) | 2021-02-23 | 2024-01-03 | Bayer Aktiengesellschaft | Furoindazole derivatives as gpr84 antagonists |
| CN115109072A (zh) * | 2021-03-18 | 2022-09-27 | 武汉人福创新药物研发中心有限公司 | 一种gpr84拮抗剂及其制备方法和用途 |
| WO2022218372A1 (zh) * | 2021-04-14 | 2022-10-20 | 武汉人福创新药物研发中心有限公司 | 一种二氢嘧啶并异喹啉酮类衍生物及用途 |
| US20240239804A1 (en) | 2021-04-29 | 2024-07-18 | Bayer Aktiengesellschaft | Furoindazole derivatives as antagonists or inhibitors of gpr84 |
| EP4355743A1 (en) | 2021-06-18 | 2024-04-24 | University of Copenhagen | Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists |
| US20240287064A1 (en) | 2021-06-21 | 2024-08-29 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Tricyclic compound used as gpr84 antagonist |
| CN115611944A (zh) | 2021-07-15 | 2023-01-17 | 中国科学院上海药物研究所 | 不对称gpr84拮抗剂及其用途 |
| WO2023076668A1 (en) * | 2021-10-29 | 2023-05-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods for treatment of cancer |
| WO2024083705A1 (en) | 2022-10-18 | 2024-04-25 | Bayer Aktiengesellschaft | Furoindazole derivatives for the treatment of pain |
| WO2024140969A1 (zh) * | 2022-12-30 | 2024-07-04 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2720085A1 (de) | 1977-05-05 | 1978-11-16 | Hoechst Ag | Pyrimido(6,1-a)isochinolin-2-on- derivate |
| ATE311884T1 (de) * | 1997-07-12 | 2005-12-15 | Cancer Rec Tech Ltd | Cyclin-abhängige-kinase inhibierende purinderivate |
| EP1165556A1 (en) * | 1999-03-31 | 2002-01-02 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| JP2007525475A (ja) * | 2003-07-08 | 2007-09-06 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
| WO2005050225A2 (en) | 2003-10-31 | 2005-06-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) |
| CA2621144A1 (en) | 2005-09-02 | 2007-03-08 | Arena Pharmaceuticals, Inc. | Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8217177B2 (en) * | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| JP2011529920A (ja) | 2008-07-31 | 2011-12-15 | ジェネンテック， インコーポレイテッド | ピリミジン化合物、組成物及び使用方法 |
| JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
| SG11201402237WA (en) | 2011-12-22 | 2014-09-26 | Novartis Ag | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives |
| AR089284A1 (es) | 2011-12-22 | 2014-08-13 | Galapagos Nv | Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios |
| MY192815A (en) | 2011-12-22 | 2022-09-09 | Connexios Life Sciences Pvt Ltd | Derivatives of aza adamantanes and uses thereof |
| MY173696A (en) | 2011-12-22 | 2020-02-17 | Connexios Life Sciences Pvt Ltd | Cyclic amide derivatives as inhibitors of 11-beta- hydroxysteroid dehydrogenase and uses thereof |
| CN104870445B (zh) | 2012-12-20 | 2017-09-15 | 加拉帕戈斯股份有限公司 | 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂) |
-
2012
- 2012-12-17 AR ARP120104774A patent/AR089284A1/es active IP Right Grant
- 2012-12-20 PL PL12812237T patent/PL2794604T3/pl unknown
- 2012-12-20 KR KR1020147020306A patent/KR102012268B1/ko active IP Right Grant
- 2012-12-20 UA UAA201408294A patent/UA111767C2/uk unknown
- 2012-12-20 US US13/721,788 patent/US8927543B2/en active Active
- 2012-12-20 EP EP17184834.4A patent/EP3378862B1/en active Active
- 2012-12-20 ES ES17184834T patent/ES2911449T3/es active Active
- 2012-12-20 WO PCT/EP2012/076275 patent/WO2013092791A1/en active Application Filing
- 2012-12-20 CN CN201280061536.3A patent/CN103998448B/zh active Active
- 2012-12-20 DK DK12812237.1T patent/DK2794604T3/da active
- 2012-12-20 EP EP22155038.7A patent/EP4019519A1/en active Pending
- 2012-12-20 DK DK17184834.4T patent/DK3378862T3/da active
- 2012-12-20 EA EA201491245A patent/EA023826B1/ru not_active IP Right Cessation
- 2012-12-20 SG SG11201403169PA patent/SG11201403169PA/en unknown
- 2012-12-20 CA CA2859578A patent/CA2859578C/en active Active
- 2012-12-20 PL PL17184834T patent/PL3378862T3/pl unknown
- 2012-12-20 LT LTEP17184834.4T patent/LT3378862T/lt unknown
- 2012-12-20 TW TW101148765A patent/TWI567073B/zh not_active IP Right Cessation
- 2012-12-20 SI SI201231991T patent/SI3378862T1/sl unknown
- 2012-12-20 BR BR112014015142-3A patent/BR112014015142B1/pt not_active IP Right Cessation
- 2012-12-20 PT PT171848344T patent/PT3378862T/pt unknown
- 2012-12-20 AU AU2012357067A patent/AU2012357067B2/en not_active Ceased
- 2012-12-20 EP EP12812237.1A patent/EP2794604B1/en active Active
- 2012-12-20 HU HUE12812237A patent/HUE12812237T4/hu unknown
- 2012-12-20 MX MX2014007363A patent/MX351681B/es active IP Right Grant
- 2012-12-20 JP JP2014547997A patent/JP6062453B2/ja active Active
- 2012-12-20 PT PT128122371T patent/PT2794604T/pt unknown
- 2012-12-20 IN IN1033MUN2014 patent/IN2014MN01033A/en unknown
- 2012-12-20 SI SI201231087T patent/SI2794604T1/sl unknown
- 2012-12-20 PE PE2014000988A patent/PE20141685A1/es active IP Right Grant
- 2012-12-20 HR HRP20220456TT patent/HRP20220456T1/hr unknown
- 2012-12-20 ES ES12812237.1T patent/ES2643379T3/es active Active
- 2012-12-20 LT LTEP12812237.1T patent/LT2794604T/lt unknown
- 2012-12-21 UY UY0001034545A patent/UY34545A/es unknown
-
2014
- 2014-01-06 US US14/148,057 patent/US9255095B2/en active Active
- 2014-05-26 PH PH12014501178A patent/PH12014501178A1/en unknown
- 2014-06-18 IL IL233212A patent/IL233212B/en active IP Right Grant
- 2014-06-19 NI NI201400060A patent/NI201400060A/es unknown
- 2014-06-20 CL CL2014001664A patent/CL2014001664A1/es unknown
- 2014-06-23 ZA ZA2014/04607A patent/ZA201404607B/en unknown
- 2014-06-24 CR CR20140305A patent/CR20140305A/es unknown
- 2014-07-22 CO CO14158655A patent/CO7010835A2/es unknown
-
2015
- 2015-03-02 HK HK15102096.2A patent/HK1201528A1/xx not_active IP Right Cessation
- 2015-12-11 US US14/966,879 patent/US10047083B2/en active Active
-
2017
- 2017-09-18 HR HRP20171404TT patent/HRP20171404T1/hr unknown
- 2017-10-11 CY CY20171101053T patent/CY1119434T1/el unknown
-
2018
- 2018-02-18 IL IL257581A patent/IL257581A/en unknown
- 2018-05-04 US US15/971,245 patent/US11220499B2/en active Active
-
2021
- 2021-11-12 US US17/454,712 patent/US20220227751A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100292T patent/CY1125167T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125167T1 (el) | Διυδροπυριμιδινοϊσοκινολινονες και φαρμακευτικες συνθεσεις αυτων για τη θεραπεια σκληρυνσης κατα πλακας | |
| CY1119422T1 (el) | Παραγωγα μπετουλινης | |
| CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| CY1119530T1 (el) | Συνθεσεις και μεθοδοι ρυθμισης toy fxr | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1122498T1 (el) | Δευτεριωμενα παραγωγα ιβακαφτορης | |
| NZ708501A (en) | Treatment of pulmonary disease | |
| CY1118682T1 (el) | Ενωσεις πυραζολης ως αναστολεις του υποδοχεα σιγμα | |
| CY1119942T1 (el) | Μεθοδοι θεραπειας της ψωριασης χρησιμοποιωντας ανταγωνιστες της il-17 | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| AR126555A2 (es) | Anticuerpos de oncostatina m humana y métodos de uso | |
| CY1120080T1 (el) | Φαρμακευτικη συνθεση περιεχουσα εναν αναστολεα hdac και εναν κυκλοπολυσακχαριτη | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| CY1116958T1 (el) | Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις | |
| EA201492285A1 (ru) | Соединения n-алкилтриазола в качестве антагонистов лизофосфатидной кислоты (lpar) | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων | |
| EA201491672A1 (ru) | Гетероциклильные соединения как ингибиторы mek | |
| CY1118610T1 (el) | Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου | |
| CY1119231T1 (el) | Θειαδιαζολιδινοδιονες ως αναστολεις της gsk-3 | |
| CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
| CY1118365T1 (el) | Διαμορφωτες διυδροπυραζολης του gpr40 | |
| MX2013011257A (es) | Proceso para la preparacion de dronedarona por n-butilacion. | |
| CU24103B1 (es) | Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos |